Anti-PNMA2 Polyclonal Antibody for WB and ELISA - Q9UL42

Core Product Specifications and Parameters

Biological Background: PNMA2 Function and Localization

• PNMA2 (Paraneoplastic antigen Ma2) is a 40 kDa neuronal protein, also known as onconeuronal antigen Ma2 or paraneoplastic neuronal antigen MM2.
• It is specifically expressed in the brain and can be aberrantly expressed in testicular tumor cells of some cancer patients.
• The protein localizes to the nucleus, with enriched presence in the nucleolus.
• Keywords associated with PNMA2 include 3D-structure, acetylation, direct protein sequencing, proteomics identification, and tumor antigen.
• PNMA2 contains experimentally verified acetylation sites and has been identified through direct protein sequencing and mass spectrometry.
• It belongs to the reference proteome for Homo sapiens and is annotated as a tumor antigen relevant to paraneoplastic syndromes.

Experimental Guidance and Technical Tips

• The immunogen spans the N‑terminal 140 amino acids of human PNMA2; consider that this region may present linear epitopes suitable for detection in denaturing Western blots.
• For Western blotting, nuclear extracts can enrich the target protein, as PNMA2 predominantly localizes to the nucleus and nucleolus.
• ELISA protocols should take into account the recombinant immunogen design; pre‑coating with the immunogen or a fragment thereof may serve as a positive control.
• Cross‑reactivity with rat has been validated; when working with rodent models, confirm antibody specificity in the relevant tissue or cell line.
• Recommended starting dilutions for each application should be determined empirically in the end‑user's experimental system.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides integrated sourcing for IVD raw materials, supporting diagnostic developers with validated antibody pairs, monoclonal/polyclonal antibodies, and ancillary reagents. For paraneoplastic antigen targets like PNMA2, we supply antibodies suited for neuro‑oncology research and assay development. Our one‑stop offering includes bulk raw‑material procurement and rare‑target sourcing, streamlining the path from concept to clinic.